JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266716

Human ERF knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ERF KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and Insertion of the selection cassette in exon 3.

View Alternative Names

ERF_HUMAN, ETS domain-containing transcription factor ERF, Ets2 repressor factor, PE-2

2 Images
Sanger Sequencing - Human ERF knockout HEK-293T cell line (AB266716)
  • Sanger seq

Unknown

Sanger Sequencing - Human ERF knockout HEK-293T cell line (AB266716)

Allele-2 : Insertion of the selection cassette in exon 3.

Sanger Sequencing - Human ERF knockout HEK-293T cell line (AB266716)
  • Sanger seq

Unknown

Sanger Sequencing - Human ERF knockout HEK-293T cell line (AB266716)

Allele-1 : 1 bp insertion in exon 3

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and Insertion of the selection cassette in exon 3

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266716-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266716 Human ERF knockout HEK-293T cell line", "number":"AB266716-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266716-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266716 Human ERF knockout HEK-293T cell line", "number":"AB266716-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ERF
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ERF or Ets2 repressor factor is a transcription factor that regulates gene expression by binding to specific DNA sequences. Sometimes referred to as ERF2 this protein has a molecular mass of around 54 kDa. ERF is widely expressed in various tissues including the liver lungs and brain. It localizes mainly in the nucleus where it interacts with DNA to modulate transcriptional activities influencing cellular responses.
Biological function summary

Ets2 repressor factor plays a role in growth regulation. It is known to negatively control the activity of other ETS transcription factors restricting their ability to activate gene expression linked with cell proliferation and differentiation. ERF is not usually part of a larger complex but can form interactions with other regulatory molecules to fine-tune cellular processes. By influencing these pathways ERF helps maintain balanced cell growth and prevent uncontrolled division.

Pathways

ERF integrates into the MAPK/ERK signaling pathway influencing cell cycle control and differentiation. This pathway also involves other proteins such as ERK2 and c-Fos which are important for transmitting signals from extracellular stimuli to the nucleus. Additionally ERF is connected to the TGF-beta signaling pathway where it aids in modulating responses to growth factors that are important in developmental processes and cellular homeostasis.

ERF has implications in cancer progression and developmental syndromes. Dysregulation of ERF gene expression can contribute to increased cell proliferation and tumor growth linking it to cancer pathways. For instance its interaction with ERK2 in the MAPK/ERK pathway influences oncogenic processes. In developmental syndromes mutations in ERF are associated with craniosynostosis a condition affecting skull development often involving altered signaling pathways related to protein FGFR2 which can result in impaired cell differentiation and growth regulation.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com